→ What’s up at Immunocore? Vantage is reporting that Immunocore’s chief strategy officer Kevin Pojasek is out, marking the latest in a long line of C-suite departure for the company. CEO Eliot Forster was first to depart, even though he was engaged in trying to raise another massive round for the company. Then there was a long string of exits, which have all been put down to personal reasons.
→ Adaptimmune $ADAP, a sister company of sorts to Immunocore, says it just raised $100 million. The TCR biotech expert, allied with GSK, sold shares to Matrix Capital Management Company, New Enterprise Associates and Syncona Portfolio Limited.
→ Loxo wasn’t the only company to get a breakthrough drug designation from the FDA today. Pfizer says it landed BTD status for PF-06651600, their JAK 3 for alopecia areata. The breakthrough designation should give them easy access to regulators as they look for an early OK, provided their Phase II data hold up.
→ Cambridge, MA-based Checkmate Pharmaceuticals has done a deal with Pfizer and Merck KGaA to run a combination study using their TLR9 agonist CMP‐001 with avelumab against advanced squamous cell cancer of the head and neck that’s proved resistant to checkpoint inhibitors.
The best place to read Endpoints News? In your inbox.
Comprehensive daily news report for those who discover, develop, and market drugs. Join 37,500+ biopharma pros who read Endpoints News by email every day.Free Subscription